TU Berlin

Health Care ManagementADVANCE_HTA

Page Content

to Navigation

ADVANCE_HTA

Advancing and strengthening the methodological tools and practices relating to the application and implementation of Health Technology Assessment (HTA)

Background

Health Technology Assessment (HTA) is widely used to inform coverage decisions in an increasing number of countries in Europe and elsewhere. A high level of debate surrounding HTA and its limitations exists, giving rise to a number of significant challenges, which are addressed in this project. For example, there is significant need to consolidate methods on interventions other than pharmaceuticals, such as medical devices, and value assessment (a detailed list of related work packages can be found below).  Overall, with the fast uptake of HTAs in many countries, there is an urgent need to work in the direction of the European initiative, EUNetHTA, aiming, among other things, to improve methods and minimize duplication of assessments across countries.

Objectives

Overall, ADVANCE_HTA aims to broaden the spectrum, complement and address areas of intense methodological debate in the application, use and implementation of HTA. Further, it aims to bring about improvements in HTA methods, which can be taken further by competent authorities at national level whilst at the same time supplementing the work of supra-national bodies, such as EUnetHTA, towards a common understanding of choices in health care decision-making.

TU Berlin is the leading partner of work package (WP) 5, which aims at identifying areas where knowledge and tools are lacking regarding the assessment of medical devices. 

Methods

  •  Taxonomy of existing classifications and nomenclatures of medical devices 
  • Systematic review to identify and compare current HTA methodologies, processes and practices across EU Member States and synthesis report 
  • Survey with HTA bodies to clarify and supplement earlier findings, and to trace methodological and procedural challenges and trends not captured in published evidence

Work Packages

WP1
Assessing Value for Money
WP2
Value Assessment of Health Technologies
WP3
HTA and Rare Diseases
WP4
HTA and Quality of Life Measurement
WP5
HTA and Medical Devices
WP6
Strengthening and implementing in emerging settings
WP7
Potential implications: Lessons learnt, Policy recommendations 
WP8
Dissemination of Project Objectives and Results 
WP9
Coordination and Management 

Partner

ADVANCE_HTA is funded under the European Commission’s 7th Framework Programme and involves thirteen partners: 

  • LSE Health (Coordinator): London School of Economics and Political Science, London, UK
  • LSHTM: London School of Hygiene and Tropical Medicine, London, UK
  • ISS: National Centre for Rare Diseases, Rome, Italy
  • UCLM: University Castilla- La Mancha Faculty of Health Science, Ciudad Real, Spain
  • IER: Institute for Economic Research, Ljubljana, Slovenia
  • EASP: Andalusian School of Public Health - University of Granada, Genada, Spain 
  • PAHO: Pan-American Health Organisation, Washington DC, USA
  • EBC: European Brain Council, Brussels, Belgium 
  • UPEC: University Paris-Est Créteil, Paris, FR
  • NICE Int: National Institute for Health and Care Excellence International, London, UK
  • AOTM: Health Technology Assessement Agency, Warsaw, Poland 
  • TLV: Dental and Pharmaceutical Benefits Board, Stockholm, Sweden 

Note

The Berlin University of Technology will host the 2nd Partners Meeting of the Consortium in November 2013.

Navigation

Quick Access

Schnellnavigation zur Seite über Nummerneingabe